Results of the ADRIATIC trial indicated that treatment with Imfinzi after standard-of-care concurrent chemoradiotherapy ...

In an interview with Pharm Exec Associate Editor Don Tracy, Karen Rodriguez-Lorenc, Global Program Head of Linvoseltamab, ...

FDA acknowledged that Astellas has resubmitted zolbetuximab for a Biologics License Application (BLA). 1 The drug is a ...

ConcertAI announced predictive and generative AI solutions, along with a variety of other products, at the 2024 ASCO Annual Meeting. While all of the products are aimed at improving research and ...

The Tarsus Pharmaceuticals CEO discusses the ways that his company is finding solutions that may have been overlooked. Bobby Azamian, CEO and chairman at Tarsus Pharmaceuticals, is focused on finding ...

Under terms of the deal, Akili will become a wholly owned subsidiary of Virtual Therapeutics, with Akili shareholders ...

Over the past 15 years, on average, racial and ethnic diversity in multiple US regions has increased by 1% to 5%. JAMA study ...

Multiple surveys show that older voters are concerned about the cost of healthcare and Medicare, along with other financial ...

Fast track designation for AV-001 comes amid promising results from a Phase I trial, which supported once-daily dosing and ...

Approval of Onyda XR marks the first liquid non-stimulant medication for attention-deficit hyperactivity disorder to hit the ...

Breyanzi, a CD19-directed CAR T-cell therapy, granted fourth FDA approval to treat a distinct subtype of non-Hodgkin lymphoma ...

Priority review designation for Keytruda is based on promising results from the Phase II/III IND.227/KEYNOTE-483 trial, which ...